GTN Modeling is a Differentiator for Life Sciences Companies
Life Sciences and Pharmaceutical manufacturers can use a consistent process across business functions and centralized, real-time data in a connected Anaplan model to more accurately forecast utilization and discounting by market segment, starting at the contract level.
By integrating gross-to-net management, manufacturers can quantitatively assess the amount of discounts flowing through each contract component and market segment, ultimately improving their ability to predict net revenue in future periods. This further enables improved accuracy of accruals and better-informed reserves, with potentially immediate impact on the bottom line.
Net Revenue Forecasting Challenges
Life Sciences & Pharmaceutical manufacturers find it difficult to forecast their net revenue because product pricing adjustments (discounts) to their gross revenue are highly complex, vary greatly across market segments and customers, and contain high-data volumes to process.
This difficulty in ability to forecast net sales directly impacts accrual management and product reserve accuracy. Moreover, due to the complexity and uniqueness of pricing adjustments, traditional spreadsheet-based approaches to forecasting lack scalability and are unable to incorporate interdependencies between market segments.
Flexibility and configurability
Native audit trail
A streamlined and centralized system
No disruption to upstream/downstream activities
High-data volumes across multiple market segments
Pharma Case Study
$500M Pharmaceutical company with 10 brands
Use Case: Revenue Accrual Reconciliation
Operational inefficiencies with no automated workflow, approvals, and audit trails
Mix of technology and manual processes that lacked scalability
Discrepancy in data sources that often drive discussions to data validation
Siloed views of information with no holistic and data-driven view of revenue accruals and/or true-ups
Inconsistency across channels & brands
Anaplan serves as a centralized platform for managing the revenue accrual reconciliation and true-up process across all customers, channels, & brand portfolios.
Every editable cell has an audit trail & end-user security to ensure proper authorization
Built a data validation at the customer and brand level to review Oracle vs Model N data in order to determine if/how many true-ups were required
Anaplan modules & formulas use predetermined custom assumptions to treat data across channels & brands the same way unless exceptions are built
With Anaplan’s systematic setup, end users can toggle model outputs across channels & brands for quick data comparisons
Improved auditability & security with a full audit-trail & documentation
Anaplan provides a flexible, scalable, & optimized platform for managing Gross-to-Net (GTN) processes
Enhanced reporting with automated outputs for better data tracking & reconciliation
Outlier data can be quickly identified
Improved deal projection accuracy & process consistency and efficiency
Automated Price Protection setup & calculation
Enabled RPU forecast & Accruals
process for systematic analysis of
GTN liabilities impact
Gross to Net
Life sciences companies operate in a highly regulated and complex environment that involves multiple functions such as research and development, clinical trials, manufacturing, supply chain management, sales, and marketing.
Anaplan can help you streamline your planning and decision-making processes across these areas by providing a unified platform that integrates data from different sources and enables cross-functional collaboration.